Post-earnings recap
Reported
Mon, Feb 1, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Haemonetics' better-than-expected EPS indicates strong performance in managing costs or improving margins. The stock's 9.01% increase reflects investor confidence in the company's ability to sustain profitability. The lack of revenue data and guidance may leave some investors cautious, but the positive EPS surprise is a good sign for the company's financial health.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.48 | N/A | +3.23% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting ongoing efforts to improve operational efficiencies. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on driving operational efficiencies.